Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ACUSENSUS LIMITED. Capital/Financing Update 2023

Feb 15, 2023

64287_rns_2023-02-15_d39b70b8-cd35-4bde-979b-ad757b7dc4bd.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [180 x 35] intentionally omitted <==

ASX RELEASE

16 February 2023

Release of securities from voluntary escrow

In accordance with ASX Listing Rule 3.10A, Acusensus Limited ( ASX:ACE ) ( Acusensus ) announces that the following securities will be released from voluntary escrow on the date when Acusensus releases it half-year results for the 2023 financial year, expected to be on or around 23 February 2023:

  • 5,015,450 ordinary shares; and

  • 300,043 options to acquire ordinary shares.

END

Enquiries Alexander Jannink Managing Director Acusensus Limited 1300 214 697 Email: [email protected]

This announcement is authorised by the Board of Acusensus Limited.

About Acusensus

Acusensus is a technology company that was founded in 2018 with a mission to design and develop artificial intelligence enabled road safety solutions. Collaborating with governments and commercial stakeholders to tackle distracted driving globally is Acusensus’ first priority.

Acusensus has pioneered intelligent solutions that provide anywhere, anytime digital evidence that can be used in conjunction with law enforcement to drive behavioural change and improve road safety. Acusensus technology is used to detect and provide prosecutable evidence of distracted driving (mobile phone use), seatbelt compliance, speeding, railway crossing compliance and the monitoring of vehicles of interest.

Acusensus listed on the Australian Securities Exchange in January 2023. Acusensus is headquartered in Melbourne, Australia, with offices also in Sydney, Brisbane, London (UK) and Las Vegas (United States).

ACUSENSUS LIMITED Level 6, 31 Queen Street Melbourne VIC 3000 Phone: 1300 214 697 [email protected] acusensus.com